ProCE Banner Activity

Nursing Considerations for CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Podcast Episodes

In this podcast, an advanced practice provider discusses the latest guidance on integrating CDK4/6 inhibitors into treatment of early-stage and metastatic HR+/HER2- breast cancer. Cases from her practice illustrate how to approach treatment selection and manage important adverse events.

Released: June 30, 2022

Expiration: June 29, 2023

No longer available for credit.

Share

Faculty

Julia A. LaBarbera

Julia A. LaBarbera, MSN, RN, AGACNP-BC

Breast Oncology
UCLA Medical Center
Los Angeles, California

Acknowledgement

This activity is supported by an educational grant from Lilly.

Provided by

ProCE Banner

Supporters

Lilly

Target Audience

Oncology NPs, PAs, and nurses

Disclosure

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics, MJH Life Sciences.

Format

Podcast

Additional Information

Program Medium

This program has been made available online.